Pharmacokinetics of simeprevir and risk of skin reactions in patients with co-infection HIV/HCV with or without a protease inhibitor containing HAART
Letizia Marinaro(University of Turin), Stefano Bonora(Ospedale Amedeo di Savoia), M. C. Tettoni, A. Airaudo, Jessica Cusato(Ospedale Amedeo di Savoia), Hamid Hasson(Vita-Salute San Raffaele University), Chiara Alcantarini, F. Favata, Francesca Di Patti(Ospedale di Sanremo), Marco Merli(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Antonio D’Avolio(Ospedale Amedeo di Savoia), Ambra Barco, Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), G. Vendemiati, Maurizio Milesi, Giovanni Di Perri(University of Turin), L. Trentini
Unknown
January 1, 2016
Cited by 0
Related Papers
Assessment, Diagnosis, and Treatment of HIV-Associated Neurocognitive Disorder: A Consensus Report of the Mind Exchange Program
|Clinical Infectious Diseases|2012|208
The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years
|BMC Geriatrics|2018|179
Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus–Infected Women: Effect of Highly Active Antiretroviral Therapy
|The Journal of Infectious Diseases|2001|173
Discontinuation of Secondary Prophylaxis against<i>Pneumocystis carinii</i>Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy
|New England Journal of Medicine|2001|168